William Crowe, MD
Urology · Lexington, KYNPI 1750387239
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.5% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Astellas Pharma US Inc at 26.0% of the total.
Across 174 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$952
- Antares Pharma, Inc.$388
- Johnson & Johnson$254
- Endo Pharmaceuticals Inc.$219
- Sumitomo Pharma America, Inc.$196
- Teleflex LLC$181
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,34691%
- Education$3129%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 48 | $952 |
| Antares Pharma, Inc. | 26 | $388 |
| Johnson & Johnson | 14 | $254 |
| Endo Pharmaceuticals Inc. | 13 | $219 |
| Sumitomo Pharma America, Inc. | 7 | $196 |
| Teleflex LLC | 3 | $181 |
| Procept Biorobotics Corporation | 3 | $178 |
| Endo USA, Inc. | 6 | $152 |
| AbbVie | 8 | $130 |
| Convatec Inc. | 4 | $128 |
| Axonics, Inc. | 5 | $85 |
| Bayer | 4 | $82 |
| Neotract Inc. | 3 | $65 |
| Blue Earth Diagnostics | 2 | $63 |
| Verity Pharmaceuticals Inc. | 3 | $63 |
| Calyxo, Inc. | 1 | $60 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| Halozyme Inc | 2 | $48 |
| 180 Medical, Inc. | 2 | $42 |
| Pfizer | 3 | $41 |
| Urovant Sciences Inc | 2 | $39 |
| Ambu Inc. | 1 | $36 |
| Dentsply IH Inc. | 2 | $26 |
| Olympus America Inc. | 1 | $25 |
| Progenics Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $23 |
| Telix Pharmaceuticals | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Boston Scientific | 1 | $17 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $17 |
| MDD US Operations, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift System$119
How this compares
$3,659 in reported general payments places this provider in the 55th percentile of 139 urology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 157 | $102,923 |
| GemtesaVibegron | 65 | $52,566 |
| Testosterone | 99 | $19,962 |
| IntrarosaPrasterone (Dhea) | 46 | $17,142 |
| XyostedTestosterone Enanthate | 21 | $14,512 |
| Mirabegron ErMirabegron | 16 | $14,385 |
| ElmironPentosan Polysulfate Sodium | 11 | $8,961 |
| Oxybutynin Chloride ErOxybutynin Chloride | 305 | $7,150 |
| Tamsulosin Hcl | 648 | $6,265 |
| Methenamine Hippurate | 111 | $6,143 |
| Tolterodine Tartrate ErTolterodine Tartrate | 39 | $4,292 |
| Testosterone Cypionate | 111 | $3,282 |
| Finasteride | 274 | $2,616 |
| Solifenacin Succinate | 72 | $2,153 |
| Desmopressin Acetate | 37 | $1,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $952 | $102,923157 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $196 | $52,56665 claims |
| Antares Pharma, Inc.Xyosted | $388 | $14,51221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 139 urology providers in Kentucky.
Other urology in Lexington
- Thomas SlabaughLexington$102K
- Patrick HensleyLexington$50K
- Stephen MonnigLexington$18K
- Frances MartinLexington$11K
- Andrew ToddLexington$9K
- Terrence GrimmLexington$9K
- Andrew HarrisLexington$8K
- James AngelLexington$8K
- Justin JohnsonLexington$7K
- Fred HadleyLexington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.